New Ionis Data Supports Olezarsen as Potential Treatment for Severe Hypertriglyceridemia

Ionis Pharmaceuticals is set to present new data from pivotal studies CORE and CORE2 supporting the use of olezarsen for treating severe hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides in the blood. The company will present these findings at upcoming congresses.